피부과 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 치료법별, 유형별, 투여 경로별, 약제 클래스별, 유통 채널별, 지역별, 경쟁별(2020-2030F)
Dermatological Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy, By Type, By Route of Administration, By Drug Class, By Distribution Channel, By Region & Competition, 2020-2030F
세계의 피부과 치료제 시장 규모는 2024년에 217억 5,000만 달러에 달하며, 2030년까지 CAGR은 9.05%로, 예측 기간 중 눈부신 성장을 달성할 것으로 예측됩니다.
피부과 치료제는 다양한 피부 질환 및 장애의 치료와 관리를 위해 특별히 고안된 의약품입니다. 피부과학은 피부, 모발, 손톱, 점막에 영향을 미치는 질병 및 상태의 진단, 치료 및 예방에 초점을 맞춘 의학의 전문 분야입니다. 피부과 치료제는 일반적인 피부 질환부터 복잡한 질환에 이르기까지 다양한 피부과적 문제를 해결하는 데 중요한 역할을 합니다. 이러한 피부과 치료제는 종종 주사나 점적투여로 투여되는 새로운 유형의 피부과 치료제입니다. 건선, 습진, 천포창과 같은 자가면역성 피부 질환에 사용됩니다. 생물제제는 특정 면역계 성분을 표적으로 삼아 염증을 억제하고 증상을 관리합니다. 일부 피부 질환은 전신에 작용하는 치료가 필요한 경우도 있습니다. 이러한 약제에는 코르티코스테로이드, 면역억제제, 표적치료제 등이 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
217억 5,000만 달러 |
| 시장 규모 : 2030년 |
366억 6,000만 달러 |
| CAGR: 2025-2030년 |
9.05% |
| 급성장 부문 |
국소 |
| 최대 시장 |
북미 |
여드름, 건선, 습진, 피부암, 피부염 등 다양한 피부질환의 높은 유병률이 피부과 치료제 수요를 견인하고 있습니다. 피부질환은 전 세계 인구의 상당 부분에 영향을 미치고 있으며, 이는 안정적인 시장 수요로 이어지고 있습니다. 전 세계 고령화 사회에서는 피부암, 노화에 따른 피부 증상 등 피부과적 문제가 발생하기 쉽습니다. 노인 인구 증가에 따라 노화 증상에 대한 피부과 치료제 수요도 증가하고 있습니다. 지속적인 연구개발 노력의 결과로 피부질환에 대한 혁신적인 치료법과 약물이 발견되고 있습니다. 생물제제, 표적치료제, 신약의 발전이 시장 성장에 기여하고 있습니다. 주름 개선 및 피부 회춘과 같은 미용 피부과 및 미용 치료에 대한 관심이 높아지면서 화장품 및 미용 산업에서 피부과 치료제 및 시술에 대한 수요가 증가하고 있습니다. 오염과 기후 변화와 같은 환경적 요인은 피부 문제를 유발할 수 있습니다. 이러한 환경 문제는 오염과 관련된 피부 문제를 해결하는 피부과 치료제에 대한 수요를 촉진할 수 있습니다.
주요 시장 성장 촉진요인
피부질환 유병률 증가
주요 시장이 해결해야 할 과제
저항과 내성
주요 시장 동향
맞춤형 의료
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 피부과 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 치료법별(여드름, 건선, 주사, 탈모증, 기타)
- 유형별(처방약, 일반의약품)
- 투여 경로별(국소, 경구, 비경구)
- 약제 클래스별(코르티코스테로이드, 레티노이드, 항생제, 항진균제, 칼시뉴린 저해제, 기타)
- 유통 채널별(병원 약국, 소매 약국, 기타)
- 지역별
- 기업별(2024)
- 시장 맵
제6장 북미의 피부과 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 북미 : 국가별 분석
제7장 유럽의 피부과 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 피부과 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 아시아태평양 : 국가별 분석
제9장 남미의 피부과 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 피부과 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 피부과 치료제 시장 : SWOT 분석
제14장 경쟁 구도
- AbbVie Inc.
- Pfizer Inc.
- Glaxo Smith Kline PLC
- Sun Pharmaceutical Industries Ltd
- Galderma SA
- Amgen Inc
- Johnson & Johnson Services, Inc.
- Novartis AG
- Almirall, S.A
- Eli Lilly and Company
- Bausch Health Companies Inc.
제15장 전략적 제안
제16장 조사회사 소개·면책사항
KSA
Global Dermatological Drugs Market was valued at USD 21.75 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 9.05% through 2030. Dermatological drugs are medications specifically designed for the treatment and management of various skin conditions and disorders. Dermatology is a medical specialty that focuses on the diagnosis, treatment, and prevention of diseases and conditions affecting the skin, hair, nails, and mucous membranes. Dermatological drugs play a crucial role in addressing a wide range of dermatological issues, from common skin conditions to more complex disorders. These are a newer class of dermatological drugs that are often administered as injections or infusions. They are used for autoimmune skin diseases like psoriasis, eczema, and pemphigus vulgaris. Biologics target specific immune system components to reduce inflammation and manage symptoms. Some dermatological conditions require systemic treatments that affect the entire body. These medications can include corticosteroids, immunosuppressive drugs, and targeted therapies.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 21.75 Billion |
| Market Size 2030 | USD 36.66 Billion |
| CAGR 2025-2030 | 9.05% |
| Fastest Growing Segment | Topical |
| Largest Market | North America |
The high prevalence of various skin conditions, including acne, psoriasis, eczema, skin cancer, and dermatitis, drives the demand for dermatological drugs. Skin conditions affect a significant portion of the global population, leading to a consistent market demand. The global aging population is more prone to dermatological issues, including skin cancers and age-related skin conditions. As the elderly population increases, the demand for dermatological drugs for conditions associated with aging also rises. Ongoing research and development efforts result in the discovery of innovative treatments and drugs for dermatological conditions. Advancements in biologics, targeted therapies, and novel formulations contribute to market growth. The growing interest in cosmetic dermatology and aesthetic treatments, such as wrinkle reduction and skin rejuvenation, boosts the demand for dermatological drugs and procedures in the cosmetic and beauty industry. Environmental factors, such as pollution and climate change, can lead to skin issues. These environmental concerns can drive the demand for dermatological drugs that address pollution-related skin problems.
Key Market Drivers
Rising Prevalence of Skin Diseases
The rising prevalence of skin diseases is one of the most significant drivers propelling the growth of the global dermatological drugs market. As skin disorders become more widespread due to environmental, genetic, and lifestyle-related factors, the demand for effective pharmaceutical treatments continues to surge. This trend creates substantial opportunities for pharmaceutical companies, biotechnology firms, and healthcare providers. Skin diseases are among the most common health conditions worldwide, affecting millions of individuals across different demographics. Skin diseases represent the most prevalent category of human illnesses, impacting approximately 900 million individuals worldwide at any given time. According to the Global Burden of Disease Project, dermatological conditions rank as the fourth leading contributor to the global non-fatal disease burden, underscoring their significant impact on healthcare systems, workforce productivity, and pharmaceutical demand. The Global Burden of Disease (GBD) study ranks skin disorders among the top 10 causes of non-fatal disability worldwide. Chronic dermatological conditions such as psoriasis, eczema, acne, rosacea, vitiligo, and skin infections require long-term management, increasing the demand for prescription and over-the-counter (OTC) dermatological drugs. As a result, pharmaceutical companies are focusing on expanding their product portfolios, leading to market growth through increased drug production and sales.
Key Market Challenges
Resistance and Tolerance
Resistance to topical antibiotics can develop in the treatment of conditions like acne and impetigo. Prolonged use of antibiotics may lead to the development of antibiotic-resistant strains of bacteria on the skin. Resistance to antifungal drugs can occur in the treatment of fungal skin infections, such as dermatophytosis (ringworm) and candidiasis. Fungi can develop resistance to commonly used antifungal agents. Prolonged use of topical corticosteroids can lead to skin thinning and tolerance, where the drug becomes less effective in managing inflammatory skin conditions like eczema and psoriasis. In some cases, acne-causing bacteria can become resistant to antibiotics commonly used in acne treatment. This has led to the development of alternative treatments and the importance of antibiotic stewardship. Some individuals may develop tolerance to OTC products like benzoyl peroxide or salicylic acid when used for acne for acne. This may necessitate a change in treatment or the addition of other therapies. In conditions like psoriasis, the immune system can become resistant to certain treatments, such as topical corticosteroids or phototherapy. This may require the use of different classes of drugs or combination therapies. Dermatologists often use combination therapies that target multiple aspects of a skin condition to reduce the risk of resistance or tolerance. This approach can include combining topical medications, systemic treatments, and non-pharmacological interventions.
Key Market Trends
Personalized Medicine
Individuals can respond differently to dermatological treatments due to genetic variations. Personalized medicine seeks to identify these genetic factors to predict treatment responses and outcomes accurately. Pharmacogenomics is the study of how an individual's genetic makeup influences their response to medications. In dermatology, this is particularly relevant for drugs used to treat conditions like psoriasis and acne. Personalized medicine is crucial in the treatment of skin cancers, such as melanoma. Genetic profiling of tumors can guide treatment decisions, including the use of targeted therapies and immunotherapies. Genetic factors play a role in atopic dermatitis (eczema). Personalized medicine can help identify specific genetic markers that influence disease severity and treatment response, allowing for tailored interventions. Genetic testing and molecular diagnostics can help dermatologists select the most appropriate treatment for specific skin conditions, ensuring better outcomes and minimizing side effects. Some companies have developed customized topical treatments based on individual skin characteristics and needs. These formulations are designed to address specific skin concerns, such as acne or hyperpigmentation. Personalized medicine can identify genetic risk factors for skin conditions like skin cancer. Patients with a higher genetic risk may receive more frequent screenings and preventive interventions. By tailoring treatments based on an individual's genetic profile, dermatologists can minimize the risk of adverse effects and optimize treatment safety and efficacy.
Key Market Players
- AbbVie Inc.
- Pfizer Inc.
- Glaxo Smith Kline PLC
- Sun Pharmaceutical Industries Ltd
- Galderma SA
- Amgen Inc
- Johnson & Johnson Services, Inc.
- Novartis AG
- Almirall, S.A
- Eli Lilly and Company
- Bausch Health Companies Inc.
Report Scope:
In this report, the Global Dermatological Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Dermatological Drugs Market, By Therapy Type:
- Acne
- Psoriasis
- Rosacea
- Alopecia
- Others
Dermatological Drugs Market, By Type:
- Prescription
- Over-the-counter
Dermatological Drugs Market, By Route of Administration:
Dermatological Drugs Market, By Drug Class:
- Corticosteroids
- Retinoids
- Antibiotics
- Antifungals
- Calcineurin Inhibitors
- Others
Dermatological Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Dermatological Drugs Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Dermatological Drugs Market.
Available Customizations:
Global Dermatological Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Dermatological Drugs Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Therapy (Acne, Psoriasis, Rosacea, Alopecia, Others)
- 5.2.2. By Type (Prescription, Over-the-counter)
- 5.2.3. By Route of Administration (Topical, Oral, Parenteral)
- 5.2.4. By Drug Class (Corticosteroids, Retinoids, Antibiotics, Antifungals, Calcineurin Inhibitors, Others)
- 5.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
- 5.2.6. By Region
- 5.2.7. By Company (2024)
- 5.3. Market Map
6. North America Dermatological Drugs Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Therapy
- 6.2.2. By Type
- 6.2.3. By Route of Administration
- 6.2.4. By Drug Class
- 6.2.5. By Distribution Channel
- 6.2.6. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Dermatological Drugs Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Therapy
- 6.3.1.2.2. By Type
- 6.3.1.2.3. By Route of Administration
- 6.3.1.2.4. By Drug Class
- 6.3.1.2.5. By Distribution Channel
- 6.3.2. Canada Dermatological Drugs Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Therapy
- 6.3.2.2.2. By Type
- 6.3.2.2.3. By Route of Administration
- 6.3.2.2.4. By Drug Class
- 6.3.2.2.5. By Distribution Channel
- 6.3.3. Mexico Dermatological Drugs Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Therapy
- 6.3.3.2.2. By Type
- 6.3.3.2.3. By Route of Administration
- 6.3.3.2.4. By Drug Class
- 6.3.3.2.5. By Distribution Channel
7. Europe Dermatological Drugs Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Therapy
- 7.2.2. By Type
- 7.2.3. By Route of Administration
- 7.2.4. By Drug Class
- 7.2.5. By Distribution Channel
- 7.2.6. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Dermatological Drugs Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Therapy
- 7.3.1.2.2. By Type
- 7.3.1.2.3. By Route of Administration
- 7.3.1.2.4. By Drug Class
- 7.3.1.2.5. By Distribution Channel
- 7.3.2. United Kingdom Dermatological Drugs Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Therapy
- 7.3.2.2.2. By Type
- 7.3.2.2.3. By Route of Administration
- 7.3.2.2.4. By Drug Class
- 7.3.2.2.5. By Distribution Channel
- 7.3.3. Italy Dermatological Drugs Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Therapy
- 7.3.3.2.2. By Type
- 7.3.3.2.3. By Route of Administration
- 7.3.3.2.4. By Drug Class
- 7.3.3.2.5. By Distribution Channel
- 7.3.4. France Dermatological Drugs Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Therapy
- 7.3.4.2.2. By Type
- 7.3.4.2.3. By Route of Administration
- 7.3.4.2.4. By Drug Class
- 7.3.4.2.5. By Distribution Channel
- 7.3.5. Spain Dermatological Drugs Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Therapy
- 7.3.5.2.2. By Type
- 7.3.5.2.3. By Route of Administration
- 7.3.5.2.4. By Drug Class
- 7.3.5.2.5. By Distribution Channel
8. Asia-Pacific Dermatological Drugs Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Therapy
- 8.2.2. By Type
- 8.2.3. By Route of Administration
- 8.2.4. By Drug Class
- 8.2.5. By Distribution Channel
- 8.2.6. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Dermatological Drugs Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Therapy
- 8.3.1.2.2. By Type
- 8.3.1.2.3. By Route of Administration
- 8.3.1.2.4. By Drug Class
- 8.3.1.2.5. By Distribution Channel
- 8.3.2. India Dermatological Drugs Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Therapy
- 8.3.2.2.2. By Type
- 8.3.2.2.3. By Route of Administration
- 8.3.2.2.4. By Drug Class
- 8.3.2.2.5. By Distribution Channel
- 8.3.3. Japan Dermatological Drugs Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Therapy
- 8.3.3.2.2. By Type
- 8.3.3.2.3. By Route of Administration
- 8.3.3.2.4. By Drug Class
- 8.3.3.2.5. By Distribution Channel
- 8.3.4. South Korea Dermatological Drugs Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Therapy
- 8.3.4.2.2. By Type
- 8.3.4.2.3. By Route of Administration
- 8.3.4.2.4. By Drug Class
- 8.3.4.2.5. By Distribution Channel
- 8.3.5. Australia Dermatological Drugs Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Therapy
- 8.3.5.2.2. By Type
- 8.3.5.2.3. By Route of Administration
- 8.3.5.2.4. By Drug Class
- 8.3.5.2.5. By Distribution Channel
9. South America Dermatological Drugs Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Therapy
- 9.2.2. By Type
- 9.2.3. By Route of Administration
- 9.2.4. By Drug Class
- 9.2.5. By Distribution Channel
- 9.2.6. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Dermatological Drugs Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Therapy
- 9.3.1.2.2. By Type
- 9.3.1.2.3. By Route of Administration
- 9.3.1.2.4. By Drug Class
- 9.3.1.2.5. By Distribution Channel
- 9.3.2. Argentina Dermatological Drugs Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Therapy
- 9.3.2.2.2. By Type
- 9.3.2.2.3. By Route of Administration
- 9.3.2.2.4. By Drug Class
- 9.3.2.2.5. By Distribution Channel
- 9.3.3. Colombia Dermatological Drugs Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Therapy
- 9.3.3.2.2. By Type
- 9.3.3.2.3. By Route of Administration
- 9.3.3.2.4. By Drug Class
- 9.3.3.2.5. By Distribution Channel
10. Middle East and Africa Dermatological Drugs Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Therapy
- 10.2.2. By Type
- 10.2.3. By Route of Administration
- 10.2.4. By Drug Class
- 10.2.5. By Distribution Channel
- 10.2.6. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Dermatological Drugs Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Therapy
- 10.3.1.2.2. By Type
- 10.3.1.2.3. By Route of Administration
- 10.3.1.2.4. By Drug Class
- 10.3.1.2.5. By Distribution Channel
- 10.3.2. Saudi Arabia Dermatological Drugs Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Therapy
- 10.3.2.2.2. By Type
- 10.3.2.2.3. By Route of Administration
- 10.3.2.2.4. By Drug Class
- 10.3.2.2.5. By Distribution Channel
- 10.3.3. UAE Dermatological Drugs Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Therapy
- 10.3.3.2.2. By Type
- 10.3.3.2.3. By Route of Administration
- 10.3.3.2.4. By Drug Class
- 10.3.3.2.5. By Distribution Channel
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Dermatological Drugs Market: SWOT Analysis
14. Competitive Landscape
- 14.1. AbbVie Inc.
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
- 14.2. Pfizer Inc.
- 14.3. Glaxo Smith Kline PLC
- 14.4. Sun Pharmaceutical Industries Ltd
- 14.5. Galderma SA
- 14.6. Amgen Inc
- 14.7. Johnson & Johnson Services, Inc.
- 14.8. Novartis AG
- 14.9. Almirall, S.A
- 14.10.Eli Lilly and Company
- 14.11.Bausch Health Companies Inc.
15. Strategic Recommendations
16. About Us & Disclaimer
